Beta-blocker therapy for patients with acute myocardial infarction

Circulation Journal

Volumn 75, Issue 8, 2011, Pages 1829-1830

  Seino, Yoshihiko ^a  

^a NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE A; GELATINASE B; RAPAMYCIN;

ACUTE HEART INFARCTION; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; EDITORIAL; HEART EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HUMAN; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; SURVIVAL RATE;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ANGIOPLASTY, BALLOON, CORONARY; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BISOPROLOL; CARBAZOLES; FEMALE; HUMANS; MALE; MYOCARDIAL INFARCTION; PROPANOLAMINES; RENIN-ANGIOTENSIN SYSTEM;

EID: 79960797478     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0643     Document Type: Editorial

References (9)

1. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta-blocker during and after myocardial infarction; an overview of the randomized trials. Prog Cardiovasc Dis 1885; 27: 335-371.
2. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 25: 43F-49F.
3. Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction. J Am Coll Cardiol 2008; 51: 210-247.
4. The CAPRICORN Investigators.Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomized trial.Lancet 2001; 357: 1385-1390.
5. Doughty RN, Whalley GA, Walsh HA, Gamble GD, Lopez- Sendon J, Sharpe N, et al. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: The CAPRICORN echo substudy. Circulation 2004; 109: 201-206.
6. Cleland JGF, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW, Murray GD, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with herat failure (CHRISTMAS trial): Randomized controlled trial. Lancet 2003; 362: 14-21.
7. Kernis SJ, Harjai KJ, Stone GW, Grines LL, Boura JA, O'Neill WW, et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty? J Am Coll Cardiol 2004; 43: 1773-1779.
8. Konishi M, Haraguchi G, Yoshikawa S, Kimura S, Inagaki H, Isobe M. Additive effects of β-blockers on renin-angiotensin system inhibitors for patients after acute myocardial infarction treated with primary coronary revascularization. Circ J 2011; 75: 198-1991.
9. Ozasa N, Kimura T, Morimoto T, Hou H, Tamura T, Shizuta S, et al. Lack of effect of oral beta-blocker therapy at discharge on longterm clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention. J Am Coll Cardiol 2010; 106: 1225-1233.